SpyGlass Pharma Q3 2026: Loss Widens as Build-Out Costs Surge

SpyGlass Pharma posted a GAAP net loss of $0.73 per share for Q3 2026, missing expectations. The company remains pre-commercial with no revenue, so the earnings report is entirely a story about spending and pipeline progress.

The biggest driver of the wider loss was a jump in general and administrative expenses, which rose to $16.2 million in the quarter. That increase reflects higher professional fees and personnel costs tied to commercial build-out ahead of any regulatory approval. R&D spending also climbed as Phase 3 enrollment for the BIM-IOL System accelerated.

The quarter's most consequential strategic move was the acquisition of Advanced Vision Science from Santen Pharmaceutical for roughly $13.0 million in cash. That deal gives SpyGlass scalable in-house manufacturing of the intraocular lens at the core of its BIM-IOL System, removing a key dependency ahead of a commercial launch. The company also completed the first patient implantations in the BIM-DRS first-in-human trial, extending its drug delivery platform to glaucoma patients who have already had cataract surgery.

On the clinical side, four-year follow-up data from the BIM-IOL first-in-human trial showed a 37% mean reduction in intraocular pressure and 86% of patients remaining free of topical IOP-lowering drops. Phase 3 enrollment remains on track to complete in 2027, with preliminary BIM-DRS safety and efficacy data also expected that year. The company plans to pursue a 505(b)(2) NDA pathway with the FDA for the BIM-IOL System.

With $215.8 million in cash on hand, management says it has sufficient runway to fund operations through 2028. That cushion matters given the sequential pattern of widening per-share losses over the past year. How quickly operating expenses stabilize as the Phase 3 trials mature will be a key variable for investors to monitor alongside the 2027 enrollment completion milestone.